{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:58:11Z","timestamp":1793224691584,"version":"4.5.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Cardiovascular and renal complications remain leading causes of morbidity and mortality among individuals with type 2 diabetes mellitus (T2DM). Since 2015, large-scale cardiovascular outcome trials (CVOTs) have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce the risk of major adverse cardiovascular events, cardiovascular mortality, and heart failure hospitalization in patients with T2DM and established cardiovascular disease or high-risk profiles. These findings\u2014originating from landmark trials such as EMPA-REG OUTCOME, LEADER, and SUSTAIN-6\u2014have led to substantial revisions in international guidelines from the European Society of Cardiology, American College of Cardiology, and American Heart Association, which now recommend the use of SGLT2i or GLP-1 RAs, often in conjunction with metformin. SGLT2i have shown robust effects in reducing heart failure hospitalization and slowing the progression of chronic kidney disease, while GLP-1 RAs have demonstrated superior efficacy in reducing atherothrombotic events, particularly non-fatal stroke. Additionally, emerging data supports the complementary use of both drug classes, revealing additive benefits on cardiovascular and renal outcomes without increased toxicity. This narrative review summarizes the mechanisms of action, clinical efficacy, safety profiles, and sex-specific outcomes associated with SGLT2i and GLP-1 RAs. It also highlights key evidence supporting their combined use and underscores their critical role in optimizing long-term outcomes in patients with T2DM and cardiovascular disease.<\/jats:p>","DOI":"10.3389\/fendo.2025.1605746","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:10:26Z","timestamp":1751847026000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists \u2013 a comprehensive review"],"prefix":"10.3389","volume":"16","author":[{"given":"David","family":"Aristiz\u00e1bal-Colorado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Corredor-Rengifo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Sierra-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"L\u00f3pez-Corredor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David-Alexander","family":"Vernaza-Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Weir-Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan S.","family":"Izquierdo-Condoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Ortiz-Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Rico-Fontalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Esteban","family":"G\u00f3mez-Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin","family":"Abreu-Lomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfredo-Antonio","family":"Rivera-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"E84","DOI":"10.5888\/pcd19.220347","article-title":"Global responses to prevent, manage, and control cardiovascular diseases","volume":"19","author":"Coronado","year":"2022","journal-title":"Prev Chronic Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications","volume":"26","author":"Dal Canto","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e016947","DOI":"10.1161\/JAHA.120.016947","article-title":"Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: findings from the look AHEAD study","volume":"10","author":"Kaze","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.12688\/f1000research.125549.3","article-title":"Prevalence and determinants of obesity among individuals with diabetes in Indonesia","volume":"11","author":"Azam","year":"2022","journal-title":"F1000Research"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihac060","article-title":"Prevalence of hypertension among type 2 diabetes mellitus patients in Ethiopia: a systematic review and meta-analysis","volume":"15","author":"Haile","year":"2023","journal-title":"Int Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.116.002901","article-title":"Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence","volume":"9","author":"Rodr\u00edguez-Guti\u00e9rrez","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diacare.10.1.1","article-title":"Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group","volume":"10","year":"1987","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6898","article-title":"Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials","volume":"343","author":"Hemmingsen","year":"2011","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.05.010","article-title":"Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Monami","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2022.2079495","article-title":"Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age \u226560years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies","volume":"17","author":"Crabtree","year":"2022","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/00033197231183229","article-title":"GLP-1 receptor agonists and SGLT-2 inhibitors in patients with versus without cardiovascular disease: A systematic review, meta-analysis, and trial sequential analysis","volume":"75","author":"Kilickap","year":"2024","journal-title":"Angiology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly","year":"2022","journal-title":"Diabetologia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-024-00706-9","article-title":"Comment on \u201cSGLT2 inhibitors, and how they work beyond the glucosuric effect\u201d","volume":"25","author":"Peronard","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"ehad192","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on SGLT2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-024-00673-1","article-title":"SGLT2 inhibitors and how they work beyond the glucosuric effect. State of the art","volume":"24","author":"Aristiz\u00e1bal-Colorado","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-021-00529-8","article-title":"SGLT2 inhibitors and their mode of action in heart failure-has the mystery been unravelled","volume":"18","author":"Pabel","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-023-01134-0","article-title":"Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter","volume":"31","author":"Hiraizumi","year":"2024","journal-title":"Nat Struct Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1174692","article-title":"Comprehensive review of SGLT2 inhibitors\u2019 efficacy through their diuretic mode of action in diabetic patients","volume":"14","author":"Lam-Chung","year":"2023","journal-title":"Front Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B32","article-title":"Risks vs benefits for SGLT2 inhibitor medications","volume":"35","author":"Pittampalli","year":"2018","journal-title":"Fed Pract"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMc1712572","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-024-00707-8","article-title":"Author\u2019s reply to Peronard and Mayntz: \u201cSGLT2 inhibitors, and how they work beyond the glucosuric effect","volume":"25","author":"Aristiz\u00e1bal-Colorado","year":"2025","journal-title":"\u201d Am J Cardiovasc Drugs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S013","article-title":"13. Older adults: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: A report of the American College of Cardiology Solution set oversight committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.10.029","article-title":"Safety of sodium-glucose co-transporter 2 inhibitors","author":"McGill","year":"2019","journal-title":"Am J Cardiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/ph16060836","article-title":"Multifaceted roles of GLP-1 and its analogs: A review on molecular mechanisms with a cardiotherapeutic perspective","volume":"16","author":"Pandey","year":"2023","journal-title":"Pharm Basel Switz"},{"key":"B41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2018.11.008","article-title":"GLP-1 receptor agonists and cardiovascular outcome trials: An update","volume":"60","author":"Andrikou","year":"2019","journal-title":"Hell J Cardiol HJC Hell Kardiologike Epitheorese"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e20240101","DOI":"10.1590\/2175-8239-JBN-2024-0101en","article-title":"Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective","volume":"46","author":"Rico-Fontalvo","year":"2024","journal-title":"J Bras Nefrol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13300-016-0155-1","article-title":"A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus","volume":"7","author":"Kayaniyil","year":"2016","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr Publ Am Diabetes Assoc"},{"key":"B47","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/CIRCRESAHA.121.319874","article-title":"GLP1R attenuates sympathetic response to high glucose via carotid body inhibition","volume":"130","author":"Pauza","year":"2022","journal-title":"Circ Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091084.46500.BB","article-title":"Oxygen\u00a0free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment","volume":"108","author":"Maack","year":"2003","journal-title":"Circulation"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabetes Stud RDS"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajem.2024.01.010","article-title":"GLP-1 agonists: A review for emergency clinicians","volume":"78","author":"Long","year":"2024","journal-title":"Am J Emerg Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e39799","DOI":"10.1097\/MD.0000000000039799","article-title":"GLP-1 receptor agonist\u2013induced diabetic ketoacidosis: A case report","volume":"103","author":"Zhang","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1111984","article-title":"Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome","volume":"14","author":"Akiyama","year":"2023","journal-title":"Front Endocrinol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01550-5","article-title":"SGLT2 inhibitors - the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: A narrative review","volume":"15","author":"Seidu","year":"2024","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000414","article-title":"Sotagliflozin and kidney outcomes, kidney function, and albuminuria in type 2 diabetes and CKD: A secondary analysis of the SCORED trial","volume":"19","author":"Sridhar","year":"2024","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10080322","article-title":"SGLT2 inhibitors vs. GLP-1 agonists to treat the heart, the kidneys and the brain","volume":"10","author":"Rolek","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77725","article-title":"Impact of SGLT2 inhibitors on preventing heart failure hospitalizations in Colombian patients with uncontrolled type 2 diabetes mellitus","volume":"17","author":"Vernaza-Trujillo","year":"2025","journal-title":"Cureus"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.24875\/RCCAR.24000056","article-title":"Impacto en desenlaces intrahospitalarios con el inici\u00f3 de un iSGLT2 en insuficiencia card\u00edaca aguda descompensada","volume":"32","author":"Rivera-Mart\u00ednez","year":"2025","journal-title":"Rev Colomb Cardiol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2025.02.006","article-title":"Impact of early SGLT2 inhibitors prescription on acute decompensated heart failure outcomes: insights from a real-world setting","volume":"93","author":"Echeverr\u00eda","year":"2023","journal-title":"Rev Esp Cardiol Engl Ed"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: A scientific statement from the American Heart Association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","article-title":"Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial","volume":"28","author":"Ruff","year":"2022","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B85","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"B87","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102382","article-title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial","volume":"16","author":"Lee","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e45487","DOI":"10.7759\/cureus.45487","article-title":"Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: A systematic review","volume":"15","author":"Parab","year":"2023","journal-title":"Cureus"},{"key":"B92","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12933-022-01686-3","article-title":"Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms","volume":"21","author":"Verg\u00e8s","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108362","article-title":"Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis","volume":"37","author":"Li","year":"2023","journal-title":"J\u00a0Diabetes Complications"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00680-5","article-title":"Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes","volume":"10","author":"Nagahisa","year":"2019","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2023.100261","article-title":"Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure\u00a0randomized controlled trials: A systematic review and meta-analysis","volume":"26","author":"Rivera","year":"2023","journal-title":"Am\u00a0Heart Hournal Plus Cardiol Res Pract"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.02.012","article-title":"Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"B101","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","article-title":"Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial","volume":"18","author":"Clegg","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057934","article-title":"Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis\u00a0of the AMPLITUDE-O trial","volume":"145","author":"Lam","year":"2022","journal-title":"Circulation"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.06.011","article-title":"The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program","volume":"318","author":"Arnott","year":"2020","journal-title":"Int J Cardiol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/dom.14179","article-title":"Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58","volume":"23","author":"Cahn","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15185","article-title":"All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes","volume":"25","author":"Riley","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e061807","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","volume":"13","author":"Ma","year":"2023","journal-title":"BMJ Open"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838277","article-title":"The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s12020-019-02175-6","article-title":"The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis","volume":"67","author":"Guo","year":"2020","journal-title":"Endocrine"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107927","article-title":"Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials","volume":"158","author":"Patoulias","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B111","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-024-02192-4","article-title":"Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies","volume":"23","author":"Ahmad","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.amjmed.2024.04.032","article-title":"Combined sodium-glucose-transporters inhibitors and glucagon-like-peptide receptor agonist compared with monotherapy improves long-term survival: A real-world registry","volume":"137","author":"Garc\u00eda-Vega","year":"2024","journal-title":"Am J Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02118-6","article-title":"GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes","volume":"23","author":"Marfella","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e078242","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial","volume":"151","author":"Marx","year":"2025","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.3389\/fendo.2025.1663787","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1605746\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:48:34Z","timestamp":1755697714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1605746\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":115,"alternative-id":["10.3389\/fendo.2025.1605746"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1605746","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"article-number":"1605746"}}